Molecular and Cellular Action of HLA Class II Molecules, Gen Risk Fctrs for VL

HLA II 类分子的分子和细胞作用、VL 的基因风险因子

• 批准号: 8473760
• 负责人: SHYAM SUNDAR
• 金额: $ 12.43万
• 依托单位: BANARAS HINDU UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-01 至 2017-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8473760
• 关键词: Address; Affect; Affinity; Alleles; Antibodies; Antigen-Presenting Cells; Antigens; Aspirate substance; Automobile Driving; B-Lymphocytes; Back; Base Sequence; Binding; Brazil; Cell physiology; Cells; Cellular Immunity; Code; Collaborations; Complex; Computer Simulation; Data; Data Set; Disease; Epidemiology; Epitopes; Family; Genes; Genetic Polymorphism; Genotype; Geography; HLA-DR Antigens; HLA-DRB1; Haplotypes; Human Herpesvirus 4; Immune response; Immunity; Immunodominant Antigens; Immunologist; In Vitro; India; Individual; Infection; Instruction; Linkage Disequilibrium; MHC Class II Genes; Mass Spectrum Analysis; Measures; Messenger RNA; Molecular; Parasites; Pattern; Peptides; Phase; Process; Proteins; Publications; Research Design; Risk; Risk Factors; Role; SNP genotyping; Signal Transduction; T-Lymphocyte; Th1/Th2 Differentiation Pathway; Tissues; Trust; Vaccination; Vaccine Design; Visceral Leishmaniasis; Whole Blood; Work; base; case control; genetic risk factor; genome wide association study; genome-wide; interest; pathogen; promoter; response; theories; therapeutic vaccine; vaccine delivery

Project 4: "Molecular and cellular action of HLA class II molecules, the major genetic risk factors for VL" The studies will build on observations made during the current TMRC, in collaboration with Phase 2 of the Welcome Trust Case Control Consortium (WTCCC2), that HLA DR_DQ class 11 region contains the major genetic risk factor for visceral leishmaniasis in India (and Brazil). Four specific aims are proposed: 1. To determine transcriptional signatures in whole blood and/or splenic aspirates from active and past cases, and Quantiferon and/or antibody positive asymptomatic infected donors (Project 1), carrying risk versus protective HLA DRB1 allele groups. 2. To determine at mRNA and protein levels ex vivo, and following stimulation/infection of cells in vitro, whether cis-acting regulatory polymorphisms are functional correlates of risk and protective HLA DRB1 allele groups. 3. To purify, and identify using mass spectrometry, naturally processed leishmanial peptides from EBV transformed B cells prepared from HLA DRB1*13/*14 versus HLA DRB1*15 donors stimulated with whole crude parasite lysate prepared from a local Indian strain of L. donovani, compare with in silico predictions of epitopes and binding affinity, and develop a strategy to subvert the immune response by vaccination 4. To validate results of aim 3 by measuring antigen presenting cell function and immune response to naturally processed and predicted peptide epitopes in exposed individuals, including active and past cases, and asymptomatic infected donors.

项目4：“人类白细胞抗原II类分子的分子和细胞作用，VL的主要遗传风险因素” 研究将以在当前TMRC期间所观察到的观察为基础，与第二阶段合作 欢迎信任案例控制联盟(WTCCC2)，HLADR_DQ 11类区域包含主要 印度(和巴西)内脏利什曼病的遗传危险因素。 提出了四个具体目标： 1.测定活动期和既往患者全血和/或脾抽吸物中的转录信号 有风险的病例，以及Quantiferon和/或抗体阳性的无症状感染捐赠者(项目1) 与保护性HLADRB1等位基因组比较。 2.在体外和在体外刺激/感染细胞后，在mRNA和蛋白质水平上确定， 顺式调节多态是否是风险和保护性的HLADRB1等位基因的功能性关联 组。 3.从EBV中提纯天然加工的利什曼多肽，并用质谱仪进行鉴定 HLADRB1*13/*14制备的转化B细胞与全反式刺激的HLADRB1*15供者的比较 从当地的印度菌株多诺瓦尼乳杆菌中制备的粗制寄生虫裂解物，与电子预测中的 表位和结合亲和力，并开发一种通过接种疫苗来颠覆免疫反应的策略 4.通过检测抗原提呈细胞功能和免疫应答来验证AIM 3的结果 暴露人群中自然处理和预测的多肽表位，包括现症和既往病例， 和无症状的受感染捐赠者。